Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.
You may also be interested in...
Debut Of Merck's Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Filing will wait until after 2015, pending results of a soon-to-launch CV outcomes study of the CETP inhibitor in 30,000 patients.
Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed
Resverlogix believes its small-molecule drug RVX-208 delivers on a key goal in cardiovascular drug development - the ability to clear life-threatening plaque out of arteries - setting the firm up to succeed with its first-in-class agent where others have failed and to write its own ticket in the $35 billion cholesterol market
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.